Mai Vang, PA
Family Medicine · Hickory, NCNPI 1265465819
Payments from drug & device makers
Across 429 payments — averaging $16.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Lilly USA, LLC$548
- AstraZeneca$511
- GSK$501
- Novo Nordisk$501
- Bayer$385
- plus $3K from 35 others
What the payments were for
- Food & beverage$6,989100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 120 | $1,586 |
| Lilly USA, LLC | 33 | $548 |
| AstraZeneca | 28 | $511 |
| GSK | 24 | $501 |
| Novo Nordisk | 32 | $501 |
| Bayer | 22 | $385 |
| Pfizer | 22 | $362 |
| Dexcom, Inc. | 15 | $280 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $220 |
| Exact Sciences | 10 | $213 |
| Sanofi-aventis U.S. LLC | 10 | $204 |
| Boehringer Ingelheim | 10 | $162 |
| Amgen | 10 | $159 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $141 |
| Novartis | 7 | $125 |
| Abbott | 5 | $117 |
| Johnson & Johnson | 6 | $113 |
| Astellas Pharma US Inc | 6 | $106 |
| Nestle Healthcare Nutrition Inc. | 6 | $99 |
| Merck | 6 | $86 |
| Phathom Pharmaceuticals, Inc. | 4 | $59 |
| Xeris Pharmaceuticals, Inc. | 3 | $59 |
| Genentech USA, Inc. | 3 | $47 |
| Medtronic | 2 | $40 |
| Mylan Specialty L.p. | 2 | $38 |
| Shield Therapeutics Inc | 2 | $33 |
| Amarin Pharma, Inc. | 2 | $29 |
| Mallinckrodt Hospital Products Inc. | 1 | $28 |
| Abiomed | 1 | $28 |
| Radius Health, Inc. | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Lundbeck LLC | 1 | $23 |
| Viatris Specialty LLC | 1 | $20 |
| IBSA Pharma Inc. | 1 | $19 |
| Cequr Corporation | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Organon | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$6,989 in reported general payments places this provider in the 90th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 100 | $102,962 |
| Tresiba Flextouch U-200Insulin Degludec | 42 | $45,928 |
| RybelsusSemaglutide | 23 | $28,677 |
| MounjaroTirzepatide | 25 | $26,816 |
| TrulicityDulaglutide | 23 | $25,998 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $19,254 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 13 | $15,129 |
| JanuviaSitagliptin Phosphate | 14 | $12,490 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $12,309 |
| FarxigaDapagliflozin Propanediol | 11 | $12,282 |
| JardianceEmpagliflozin | 19 | $11,774 |
| EliquisApixaban | 14 | $10,545 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $1,897 |
| SynthroidLevothyroxine Sodium | 18 | $1,849 |
| Atorvastatin Calcium | 230 | $1,615 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $501 | $131,639123 claims |
| Lilly USA, LLCMounjaro, Trulicity | $548 | $52,81448 claims |
| GSKTrelegy Ellipta | $501 | $19,25427 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $204 | $15,12913 claims |
| MerckJanuvia | $86 | $12,49014 claims |
| AstraZenecaFarxiga | $511 | $12,28211 claims |
| Boehringer IngelheimJardiance | $162 | $11,77419 claims |
| PfizerEliquis | $362 | $10,54514 claims |
| AbbVieSynthroid | $1,586 | $1,84918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Hickory
- Jonathan WilsonHickory$12.7M
- John EarlHickory$4.7M
- Scott PolsterHickory$2.6M
- Robert HartHickory$636K
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.